Open Access

Clinical experience with triptans

  • Giorgio Zanchin1Email author,
  • Filippo Dainese1,
  • Federico Mainardi1 and
  • Ferdinando Maggioni1
The Journal of Headache and PainOfficial Journal of the Italian Society for the Study of Headaches and the Italian Society of Pain Clinicians2:21

https://doi.org/10.1007/s101940170021

Abstract

Many drugs are now available for treating migraine attacks, including agents specifically indicated for this condition. Since 1990 sumatriptan, the first 5–HT1B,1D receptor agonist, was introduced and realized a real breakthrough in therapy; other agents of this class of drugs called triptans have more recently been used. All of them are effective in relieving the symptoms of migraine, but each exhibits pharmacological and/or clinical features that must be considered for the optimal care and management of the patient. We present here a short overview on the main clinical features of the triptans already in use in Italy.

Triptans Migraine Clinical use Sumatriptan, Zolmitriptan Rizatriptan

Notes